Efficacy and safety of peginterferon plus ribavirin for patients aged≥65years with chronic hepatitis C: A systematic review and meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 4, 2014, Pages 440-450

  Yang, Zongguo ^a   Zhuang, Liping ^b,c   Yang, Lei ^d   Liu, Cheng ^a   Lu, Yunfei ^a   Xu, Qingnian ^a   Chen, Xiaorong ^a   Chen, Liang ^a  

^a SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d CHINA AEROSPACE SCIENCE AND INDUSTRY CORPORATION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; QUALITY CONTROL; RECURRENCE RISK; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG COMBINATION; HEPATITIS C, CHRONIC;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84912571122     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.08.013     Document Type: Article

References (40)

1. Omata M., Kanda T., Yu M.L., Yokosuka O., Lim S.G., Jafri W., et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012, 6:409-435.
2. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55(2):245-264.
3. Seeff L.B. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009, 29(Suppl. 1):89-99.
4. Schaefer E.A.K., Chung R.T. Anti-hepatitis C virus drugs in development. Gastroenterology 2012, 142(6):1340-1350.
5. Okayama A., Stuver S.O., Tabor E., Tachibana N., Kohara M., Mueller N.E., et al. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepat 2002, 9(1):43-51.
6. Guadaqnino V., Stroffolini T., Rapicetta M., Costantino A., Kondili L.A., Menniti-Ippolito F., et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997, 26(4):1006-1011.
7. Chen C.H., Yang P.M., Huang G.T., Lee H.S., Sung J.L., Sheu J.C. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007, 106(2):148-155.
8. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144(10):705-714.
9. Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008, 25(1):9-18.
10. Thabut D., Le Calvez S., Thibault V., Massard J., Munteanu M., Di Martino V., et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?. Am J Gastroenterol 2006, 101(6):1260-1267.
11. Tsui J.I., Currie S., Shen H., Bini E.J., Brau N., Wright T.L., et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci 2008, 53(3):809-814.
12. Grange J.D., Amiot X. Treatment of hepatitis C in elderly patients: challenge for the future or present reality?. Liver Int 2010, 30(4):493-495.
13. Huang J.F., Yu M.L., Lee C.M., Dai C.Y., Hou N.J., Hsieh M.Y., et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther 2007, 25(9):1029-1037.
14. Imai Y., Kasahara A., Tanaka H., Okanoue T., Hiramatsu N., Tsubouchi H., et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004, 39(11):1069-1077.
15. Yu J., Liu B.W., Lan L., Yuan Y., Zhang H., Jia C.H. Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010, 24(5):373-375. [In Chinese].
16. Zeuzem S., Hultcrantz R., Bourliere M., Goeser T., Marcellin P., Sanchez-Tapias J., et al. Peginterferon alpha 2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol 2004, 40(6):993-999.
17. Antonucci G., Longo M.A., Angeletti C., Vairo F., Oliva A., Comandini U.V., et al. The effect of age on response to therapy with peginterferon α plus ribavirin including subjects older than 65 years. Am J Gastroenterol 2007, 102(7):1383-1391.
18. Honda T., Katano Y., Shimizu J., Ishizu Y., Doizaki M., Hayashi K., et al. Efficacy of peginterferon-α-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010, 30(4):527-537.
19. Huang C.F., Yang J.F., Dai C.Y., Huang J.F., Hou N.J., Hsieh M.Y., et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010, 201(5):751-759.
20. Kainuma M., Furusyo N., Kajiwara E., Takahashi K., Nomura H., Tanabe Y., et al. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010, 16(35):4400-4409.
21. Oze T., Hiramatsu N., Yakushijin T., Mochizuki K., Oshita M., Hagiwara H., et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol 2011, 54(4):604-611.
22. Yu J.W., Sun L.J., Kang P., Yang B.Z., Zhao Y.H. Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatob Pancreatic Dis Int 2012, 11(2):185-192.
23. Nishikawa H., Iguchi E., Koshikawa Y., Ako S., Inuzuka T., Takeda H., et al. The effect of pegylated interferon alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes 2012, 5:135.
24. Kim H.I., Kim I.H., Jeon B.J., Lee S., Kim S.H., Kim S.W., et al. Treatment response and tolerability of pegylated interferon-α plus ribavirin combination therapy in elderly patients (≥65 years) with chronic hepatitis C in Korea. Hepat Mon 2012, 12(7):430-436.
25. Slim K., Nini E., Forestier D., Kwiatkowski F., Panis Y., Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003, 73(9):712-716.
26. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011) 2011, The Cochrane Collaboration, [Available from: www.cochrane-handbook.org].
27. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
28. Bedossa P., Poynard T. An algorithm for grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2):189-293.
29. Huang C.F., Chuang W.L., Yu M.L. Chronic hepatitis C infection in the elderly. Kaohsiung J Med Sci 2011, 27(12):533-537.
30. Yu M.L., Huang C.F., Dai C.Y., Huang J.F., Chuang W.L. Long-term effects of interferon-based therapy for chronic hepatitis C. Oncology 2007, 72(Suppl.1):16-23.
31. Pradat P., Voirin N., Tillmann H.L., Chevallier M., Trépo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int 2007, 27(3):335-359.
32. Tokita H., Fukui H., Tanaka A., Kamitsukasa H., Yagura M., Harada H., et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005, 20(5):752-758.
33. Hamada H., Yatsuhashi H., Yano K., Daikoku M., Arisawa K., Inoue O., et al. Impact of aging on the development of hepatocellular carcinoma in patients with post-transfusion chronic hepatitis C. Cancer 2002, 95(2):331-339.
34. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B., American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374.
35. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.M.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4):1433-1444.
36. Hiramatsu N., Oze T., Yakushijin T., Inoue Y., Igura T., Mochizuki K., et al. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepatitis 2009, 16:586-594.
37. Furusyo N., Murata M., Ogawa E., Toyoda K., Ihara T., Ikezaki H., et al. Ribavrin concentration in the later stages of 48-week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. J Antimicrob Chemother 2011, 66:1127-1139.
38. Hayashi N., Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006, 41(1):17-27.
39. Bruchfeld A., Lindahl K., Schvarcz R., Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002, 24(6):701-708.
40. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34(5):730-739.